肿瘤防治研究2024，Vol.51Issue(7)：588-593,6.DOI:10.3971/j.issn.1000-8578.2024.24.0088
HER2低表达乳腺癌治疗新进展
New Advances in Treatment of HER2-Low Breast Cancer
摘要
Abstract
Currently,breast cancer is a common malignancy in female,and previous guidelines recommended that one of the key biomarkers for breast cancer,human epidermal growth factor receptor 2(HER2),is classified as either positive or negative to guide clinicians'treatment decisions.While nearly half of breast cancer patients have low HER2 expression(IHC expression is 1+or 2+and ISH detection is negative),such patients are insensitive to traditional anti-HER2 targeted therapy.However,novel antibody-drug conjugates(ADCs)provide new targeted therapy options for breast cancer patients with low HER2 expression,challenging the traditional binary concept and arousing research enthusiasm.In the latest ASCO/CAP guidelines for HER2 detection in breast cancer,HER2-low breast cancer has been included as a clinical treatment subgroup.This article will review the definition of HER2-low breast cancer,the progress of drug therapy such as ADC,and the current challenges faced by this subgroup.关键词
乳腺癌/HER2低表达/抗体-药物偶联物Key words
Breast cancer/HER2-low/Antibody-drug conjugates分类
医药卫生引用本文复制引用
孜拉兰·玉山江,祖丽皮耶·买合木提,何沐钊,李鸿涛..HER2低表达乳腺癌治疗新进展[J].肿瘤防治研究,2024,51(7):588-593,6.基金项目
The Second Batch of"Tianshan Talents Cultivation Program"—Technology and Innovation Leading Talents Project(No.2023TSYCLJ0039) 第二批"天山人才培养计划"—技术创新领军人才项目(2023TSYCLJ0039) （No.2023TSYCLJ0039）
